Eli Lilly drug tirzepatide meets weight-loss goals in obesity trial
A highly anticipated clinical trial from Eli Lilly showed its Type 2 diabetes drug met its primary endpoints. CNBC’s Meg Tirrell joins ‘Squawk Box’ to break down the results.
Read More »
Wedbush’s Joel Kulina: Microsoft, Apple remain last safe havens of the market
Joel Kulina, Head of Technology/Media Trading at Wedbush Securities, joins Worldwide Exchange to discuss the tech sector outlook ahead of the anticipated Big Tech earnings reports later today.
Read More »
Matt Orton: Information technology, healthcare are areas of interest
Matt Orton of Carillon Tower Advisers joins Worldwide Exchange to give his take on what’s driving the market.
Read More »
Food prices are never going back to where they were in ’19, says Tilman Fertitta
Tilman Fertitta, Fertitta Entertainment chairman, joins ‘Power Lunch’ to discuss how his companies are doing, how inflation is impacting his business and more.
Read More »
There is still significant upside in revenue for payment stocks, says MoffettNathanson’s Ellis
Lisa Ellis, MoffettNathanson partner and senior equity analyst, joins ‘Power Lunch’ to discuss Ellis’ take on payment companies, what’s going with PayPal’s stumbles and execution issues.
Read More »
Crypto prices rebound and Solana’s co-founder thinks bitcoin needs proof of stake: CNBC Crypto World
CNBC Crypto World features the latest news and daily trading updates from the digital currency markets and provides viewers with a look at what’s ahead with high-profile interviews, explainers, and unique stories from the ever-changing crypto industry. On today’s show,…
Read More »
I won’t breathe a sigh of relief until the Nasdaq 100 is above 14,000, says Bell Curve’s Strazzullo
Bill Strazzullo, Bell Curve Trading chief market strategist, joins ‘Power Lunch’ to discuss how much further the Nasdaq 100 will fall, when he’ll feel comfortable investing in the Nasdaq 100 and more.
Read More »
Look at company cash flows and margins to avoid value traps, says DCLA’s Sethi
Sarat Sethi, DCLA managing partner, joins ‘Power Lunch’ to discuss the difference between a true value stock and a value trap, which stocks are value traps and which value stocks he believes have strong fundamentals.
Read More »